4//SEC Filing
Guenther Sven 4
Accession 0001437749-20-002100
CIK 0001434647other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 9:39 PM ET
Size
5.9 KB
Accession
0001437749-20-002100
Insider Transaction Report
Form 4
KEMPHARM, INCKMPH
Guenther Sven
Exec VP R&D
Transactions
- Award
Stock Option (right to buy)
2020-02-05+160,000→ 160,000 totalExercise: $0.37Exp: 2030-02-04→ Common Stock (160,000 underlying)
Footnotes (1)
- [F1]Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.
Documents
Issuer
KEMPHARM, INC
CIK 0001434647
Entity typeother
Related Parties
1- filerCIK 0001638368
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 9:39 PM ET
- Size
- 5.9 KB